Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group study

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 399-405

  Glade Bender, Julia L ^a   Adamson, Peter C ^a   Reid, Joel M ^a   Xu, Lu ^a   Baruchel, Sylvain ^a   Shaked, Yuval ^a   Kerbel, Robert S ^a   Cooney Qualter, Erin M ^a   Stempak, Diana ^a   Chen, Helen X ^a   Nelson, Marvin D ^a   Krailo, Mark D ^a   Ingle, Ashish M ^a   Blaney, Susan M ^a   Kandel, Jessica J ^a   Yamashiro, Darrell J ^a  

^a

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADOLESCENT; ADULT; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHILD; CHILD CARE; CHILD GROWTH; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; SOLID TUMOR; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HALF-LIFE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38649105118     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9230     Document Type: Article

References (32)

1. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
2. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
3. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
4. Miller KD, Wang W, Gralow J: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94, 2005 (suppl; abstr 3)
5. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555, 2005
6. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
7. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
8. Gerber HP, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258, 2000
9. Rowe DH, Huang J, Kayton ML, et al: Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35:30-33, 2000
10. Rowe DH, Huang J, Li J, et al: Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35:977-981, 2000
11. McCrudden KW, Hopkins B, Frischer J, et al: Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. J Pediatr Surg 38:308-314, 2003
12. Ryan AM, Eppler DB, Hagler KE, et al: Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78-86, 1999
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Pugh DG, Winkler NT: Scanography for leg-length measurement: An easy satisfactory method. Radiology 87:130-133, 1966
15. Anderson BD, Adamson PC, Weiner SL, et al: Tissue collection for correlative studies in childhood cancer clinical trials: Ethical considerations and special imperatives. J Clin Oncol 22:4846-4850, 2004
16. Philpott NJ, Turner AJ, Scopes J, et al: The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques. Blood 87: 2244-2251, 1996
17. Mancuso P, Burlini A, Pruneri G, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661, 2001
18. Rabascio C, Muratori E, Mancuso P, et al: Assessing tumor angiogenesis: Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 64:4373-4377, 2004
19. Mancuso P, Colleoni M, Calleri A, et al: Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108:452-459, 2006
20. Saif MW, Mehra R: Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 5:553-566, 2006
21. Fakih MG, Lombardo JC: Bevacizumab-induced nasal septum perforation. Oncologist 11:85-86, 2006
22. Glusker P, Recht L, Lane B, et al: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, 2006
23. Gerber HP, Vu TH, Ryan AM, et al: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628, 1999
24. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
25. Gaudreault J, Bruno R, Kabbinavar F, et al: Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing. J Clin Oncol 22:205s, 2004 (suppl; abstr 3041)
26. Avastin product information. South San Francisco, CA, Genentech Inc, 2007, p 2
27. Hsei V, Novotny W, Margolin K, et al: Population pharmacokinetic (PK) analysis of bevacizumab (BV) in cancer subjects. Proc Am Soc Clin Oncol 20:69a, 2001 (abstr 272)
28. Lu J, Gaudreault J, Novotny W, et al: A population pharmacokinetic model for bevacizumab. Clin Pharmacol Ther 75:P-91(PII-149), 2004
29. Buckstein R, Kerbel RS, Shaked Y, et al: High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12:5190-5198, 2006
30. Fürstenberger G, von Moos R, Lucas R, et al: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94:524-531, 2006
31. Norden-Zfoni A, Desai J, Manola J, et al: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13:2643-2650, 2007
32. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006